The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

Despite chill winds on Wall Street, investors continue to place bets on fledgling biotechnology companies.

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.